Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intramyocardial CD133+ autologous bone marrow stem cells during CABG after myocardial infarction
2006-006404-11Phase 3Terminated
- Sponsor
- Miltenyi Biotec
- Start
- Aug 2007
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of autologous CD133+ cells in coronary arteriosclerosis and myocardial infarction (MI) (2 arms), sponsored by Miltenyi Biotec. Primary endpoint: Left ventricular ejection fraction at 6 months. Started Aug 2007; status: terminated.
02
Drugs
autologous CD133+ cells
03
Conditions
coronary arteriosclerosismyocardial infarction (MI)
Beyond the preview
Go deeper on 2006-006404-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006404-11.